Failure of Deferasirox, an Iron Chelator Agent, Combined with Antifungals in a Case of Severe Zygomycosis
- 1 April 2008
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 52 (4), 1585-1586
- https://doi.org/10.1128/aac.01611-07
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- The iron chelator deferasirox protects mice from mucormycosis through iron starvationJCI Insight, 2007
- Deferasirox, an Iron-Chelating Agent, as Salvage Therapy for Rhinocerebral MucormycosisAntimicrobial Agents and Chemotherapy, 2006
- Deferiprone iron chelation as a novel therapy for experimental mucormycosisJournal of Antimicrobial Chemotherapy, 2006
- Novel Perspectives on Mucormycosis: Pathophysiology, Presentation, and ManagementClinical Microbiology Reviews, 2005
- Rhizopus oryzae Adheres to, Is Phagocytosed by, and Damages Endothelial Cells In VitroInfection and Immunity, 2005
- Combination Therapy with Amphotericin B Lipid Complex and Caspofungin Acetate of Disseminated Zygomycosis in Diabetic Ketoacidotic MiceAntimicrobial Agents and Chemotherapy, 2005
- Vascularites secondaires aux infections fongiquesLa Presse Médicale, 2004
- Breakthrough Zygomycosis after Voriconazole Treatment in Recipients of Hematopoietic Stem-Cell TransplantsNew England Journal of Medicine, 2004
- In vitro susceptibilities of zygomycetes to conventional and new antifungalsJournal of Antimicrobial Chemotherapy, 2002
- Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies.JCI Insight, 1993